Search
Mazindol
go.drugbank.com/drugs/DB00579ApprovedMazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.
Estazolam
go.drugbank.com/drugs/DB01215ApprovedIllicitInvestigationalIt has been shown in some cases to be more potent than diazepam or nitrazepam.
Isoprenaline
go.drugbank.com/drugs/DB01064ApprovedInvestigationalIsoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, a...
Categories: Adrenergics for Systemic Use, Drugs for Obstructive Airway DiseasesSalsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSalsalate is a nonsteroidal anti-inflammatory agent for oral administration. … Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
Imlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalThe FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with
Cataract development
go.drugbank.com/conditions/DBCOND0096028Synonyms: Cataract form (observable entity)Gadolinium
go.drugbank.com/drugs/DB12091ApprovedInvestigationalWithdrawnGadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
Categories: Compounds used in a research, industrial, or household settingPotassium alum
go.drugbank.com/drugs/DB09087ApprovedWithdrawn[L1070] It is an inorganic salt, also called potassium aluminum sulfate with a formula of AlK(SO4)2 that is predominantly produced in the dodecahydrate form (AlK(SO4)2 * 12H2O). … Potassium alum is formed by large, transparent crystals that are used in different products like food or drugs as a buffer, neutralizing or forming agent.[T60]
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIt was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]
Homatropine
go.drugbank.com/drugs/DB11181ApprovedIt is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions.